Explore more publications!
Vatican Health Times
Got News to Share?

Vatican Health Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vatican Health Times.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 3, 2025

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
December 3, 2025

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

Indeterminate GlobeNewswire
March Biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer
December 3, 2025

March Biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer

Indeterminate GlobeNewswire
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)
December 3, 2025

Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)

Indeterminate GlobeNewswire
Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)
December 3, 2025

Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)

Indeterminate GlobeNewswire
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
December 3, 2025

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Indeterminate GlobeNewswire
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
December 3, 2025

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program

Indeterminate GlobeNewswire
Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
December 3, 2025

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval

Indeterminate GlobeNewswire
Catheter Precision Secures Tender From Leading Hospital in Hungary
December 3, 2025

Catheter Precision Secures Tender From Leading Hospital in Hungary

Indeterminate GlobeNewswire
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
December 3, 2025

Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

Indeterminate GlobeNewswire
Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies
December 3, 2025

Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies

Indeterminate GlobeNewswire
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
December 3, 2025

BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno

Indeterminate GlobeNewswire
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
December 3, 2025

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Indeterminate GlobeNewswire
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
December 3, 2025

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Indeterminate GlobeNewswire
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
December 3, 2025

Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

Indeterminate GlobeNewswire
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
December 3, 2025

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Indeterminate GlobeNewswire
Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader
December 3, 2025

Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader

Indeterminate GlobeNewswire
Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline
December 3, 2025

Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline

Indeterminate GlobeNewswire
Microbix & Seegene Mexico Collaborate to Improve Test Accuracy
December 3, 2025

Microbix & Seegene Mexico Collaborate to Improve Test Accuracy

Indeterminate GlobeNewswire
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
December 3, 2025

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Indeterminate GlobeNewswire
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
December 3, 2025

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions